As clinical relevant result, we demonstrated resistance of early breast cancer with somatic PIK3CA-mutation to adjuvant aromatase inhibitor therapy, suggesting tamoxifen as preferred therapy in these patients. This evidence concerns the gene PIK3CA and breast cancer.